Comment · Wed, December 2, 2020 · ND Owner
WADA
Original post in this thread
GNATUS_THYRSI · 2 points
Looking over the ND lineup, I only see two items which WADA cares about, adrafinil and cardephon. I recently noticed that you've got B2B products which are more... potent. Should anyone subject to WADA or similar testing be concerned about cross contamination in processing/encapsulation?
What they were answering
Direct reply to the original post — see the thread post above.
u/MisterYouAreSoDumb · ND Owner
Absolutely not. There is no cross-contamination of anything at our facility. We take that seriously. Also, we don't even process the more potent products for B2B on the same machines as the rest. They are all solutions in separate rooms, so there is not even a possibility of cross-contamination.